A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer

Autor: Gbenga Kazeem, Durisala Desaiah, Christian Dittrich, Dirk Behringer, Christer Sederholm, Joachim von Pawel, Joerg T. Hartmann, Zsolt Papai-Szekely, Nuria Vinolas, Monika I. Leschinger

Publikováno v: European Journal of Cancer. 50:1571-1580

Introduction Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02cd35ff4d24248524ac5b34c8413d2
https://doi.org/10.1016/j.ejca.2014.03.007

Gemcitabin in der First-line-Therapie des lokal fortgeschrittenen und metastasierten nicht-kleinzelligen Bronchialkarzinoms (NSCLC): Ergebnisübersicht randomisierter Phase-III-Studien

Autor: Monika I. Leschinger, Frank Langer, Wolfgang H-W Schütte, Karin Helsberg

Publikováno v: Gemcitabin in der First-line-Therapie des lokal fortgeschrittenen und metastasierten nicht-kleinzelligen Bronchialkarzinoms (NSCLC): Ergebnis�bersicht randomisierter Phase-III-Studien

Beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom (NSCLC) erreichen moderne, platinbasierte Kombinationstherapien mit Gemcitabin, Vinorelbin oder Taxanen Ansprechraten von 30–40%, mediane

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ffffdd8016c328a172078e5cc5258164
https://doi.org/10.1159/000084364

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer

Autor: Gerald Schmid-Bindert, Scott P. Myrand, Veronique Ripoche, Rebecca R. Hozak, Frank Mayer, Carla Visseren-Grul, Bente Frimodt-Moller, Kostas N. Syrigos, Diego Marquez-Medina, Annamaria Zimmermann, Monika I. Leschinger, Bonne Biesma, Wolfgang Schuette, Vittorio Gebbia, Edurne Arriola, Tuan S. Nguyen

Publikováno v: Lung cancer (Amsterdam, Netherlands). 81(3)

Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). Patients and methods In this single-arm, multicenter cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe3ea5dd9e24e7705bfd9c9547b92b9
https://pubmed.ncbi.nlm.nih.gov/23790468

A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC

Autor: M. Klima, N. Vinolas, Durisala Desaiah, Christian Dittrich, Monika I. Leschinger, J. von Pawel, Zsolt Papai-Szekely, Christer Sederholm

Publikováno v: Pneumologie. 66

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abf4250f8ca75b9a2f40678c18387332
https://doi.org/10.1055/s-0032-1302878

Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany

Autor: Martin Reck, Wolfgang Schuette, Monika Serke, C. Eschbach, Joachim von Pawel, Monika I. Leschinger, Rolf A. Stahel, Meinolf Karthaus, Christian Manegold, Thomas H. Fink, Soenke Korfee

Publikováno v: Respiratory medicine. 104(1)

An international expanded access program was initiated to provide access to treatment with pemetrexed prior registration and reimbursement for malignant mesothelioma (MM). Chemonaïve and pretreated patients with inoperable MM of the pleura or perito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34a6a49965a688a3767e4029fd22b424
https://pubmed.ncbi.nlm.nih.gov/19818589